BridgeBio raises $632.5M in bond offering to fuel growth and cut debt costs
BridgeBio has secured $632.5 million through a new bond issue, aiming to cut costs and fund upcoming projects. The company also reported strong preliminary figures for 2025, with its Attruby franchise nearing major revenue milestones. Meanwhile, key clinical results and drug submissions are expected in the first half of 2026.
On January 21, 2026, BridgeBio completed a $632.5 million convertible bond offering. The funds will repay higher-interest bonds maturing in 2027, reducing the company’s interest expenses. With around $587.5 million in cash reserves, the refinancing move strengthens its financial position.
The company’s Attruby franchise continues to grow, with Q4 2025 net revenue reaching $146 million. This brought the 2025 total to $362.4 million, surpassing earlier expectations. BridgeBio now targets over $1 billion in Attruby sales for 2026, citing accelerating commercial demand.
In early January 2026, the Phase III PROPEL 3 study for infigratinib in achondroplasia completed its final patient visit. Topline results are due by the end of Q1 2026, though no data has been released yet. Additionally, BridgeBio plans to submit new drug applications (NDAs) for BBP-418 and encaleret in the first half of the year.
The bond issue and refinancing will ease BridgeBio’s debt burden while supporting its pipeline. With upcoming Phase III results and planned NDAs, the company expects further growth in 2026. Strong Attruby sales and cash reserves provide a solid foundation for these developments.
